B. Wu

Rare primary bone tuberculosis associated with ruxolitinib therapy: A case report and literature review

Rationale: Ruxolitinib, a Janus kinase (JAK) inhibitor, may increase the risk of tuberculosis infection by suppressing cellular immunity. Tuberculosis associated with ruxolitinib has generally been reported as disseminated or multisystem disease. However, no previous cases of pri...